跳转至内容
Merck

Y0000336

甲巯咪唑

European Pharmacopoeia (EP) Reference Standard

别名:

1-甲基-2-咪唑硫醇, 2-巯基-1-甲基咪唑

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C4H6N2S
CAS号:
分子量:
114.17
Beilstein:
108646
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

thiamazole

製造商/商標名

EDQM

mp

144-147 °C (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

CN1C=CNC1=S

InChI

1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)

InChI 密鑰

PMRYVIKBURPHAH-UHFFFAOYSA-N

基因資訊

human ... TPO(7173)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Thiamazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazardExclamation mark

訊號詞

Warning

危險分類

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Sens. 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Fernando Bolaños et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 54(4), 307-310 (2002-11-06)
Long-term thionamide treatment is considered one of the main resources for Graves' hyperthyroidism. Although a 54.2% remission rate in patients so treated in Mexico was previously reported, most articles have shown a wide variation over time. In the present article
Ashish A Vyas et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 16(4), 673-676 (2010-05-05)
To report a case of a patient with Graves disease presenting with agranulocytosis induced by methimazole, with subsequent thyroid storm and successful therapeutic use of plasmapheresis. The clinical features and laboratory findings in a patient with agranulocytosis and thyroid storm
M Clementi et al.
American journal of medical genetics, 83(1), 43-46 (1999-03-17)
We report on a further case of congenital anomalies in a child exposed to methimazole during the first trimester of pregnancy (from first to seventh gestational week), and define a specific malformation pattern related to prenatal methimazole exposure and consisting
T Vogt et al.
The British journal of dermatology, 133(6), 994-996 (1995-12-01)
We report a child with scalp aplasia cutis congenita, whose mother was treated with methimazole during pregnancy. The relationship between antithyroid drug administration during pregnancy and the occurrence of scalp defects is discussed, and the pertinent literature is reviewed.
P Barbero et al.
American journal of medical genetics. Part A, 129A(1), 83-86 (2004-07-22)
We report three patients with bilateral choanal atresia in children prenatally exposed to methimazole (MMI) in order to define a MMI embryopathy clinical pattern. The combination of choanal atresia and other specific malformations strongly resembles previously reported patients exposed to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门